SCHEMBL4674460

SCHEMBL4674460

O=C(O)C(O)=CC(=O)c1cc(Cc2cccc(F)c2)co1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.40
GPR52 Q9Y2T5 1/20 0.40
IDH1 O75874 1/20 0.37
SLC1A1 P43005 2/20 0.36
SRC P12931 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
NR4A2 P43354 2/20 0.36
RAB9A P51151 2/20 0.36
MAPK1 P28482 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM5A P29375 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
GSK3B P49841 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674457 1.00 HCAR2 (0.40) HCAR2GPR52IDH1SLC1A1SRC
SCHEMBL4675016 0.86 IDH1 (0.38) GPR52IDH1LMNA
SCHEMBL4675020 0.86 IDH1 (0.38) GPR52IDH1LMNA
SCHEMBL4673710 0.85 CTBP2 (0.35) LMNARAB9AMAPK1
SCHEMBL4673707 0.85 CTBP2 (0.35) LMNARAB9AMAPK1
SCHEMBL4673996 0.80 GPR52 (0.41) HCAR2GPR52IDH1SLC1A1LMNA
SCHEMBL4673991 0.80 GPR52 (0.41) HCAR2GPR52IDH1SLC1A1LMNA
SCHEMBL4677614 0.80 PTPN1 (0.43) GPR52RAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL4677607 0.80 PTPN1 (0.43) GPR52RAB9AMAPK1NPC1SMN1; SMN2
SCHEMBL4673573 0.80 NR4A1 (0.41) HCAR2GPR52LMNAPOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885GPR52 2542/4885IDH1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.